Reformulations of pseudoephedrine- and ephedrine-containing drugs
in the UK look unlikely following the announcement of less extreme
restrictions on the sale of the pharmaceuticals.
Drugs containing pseudoephedrine and ephedrine could soon be
reclassified as prescription-only the UK, in proposals drawn up
last week by the Medicines and Healthcare Products Regulatory
Agency (MHRA).
US firm SCOLR Pharma has dropped development plans for a controlled
release phenylephrine (PE) formulation, in light of slow progress
in the over-the-counter (OTC) PE market.
Major drug companies across the US have scrambled to reformulate
their over-the-counter cold medications in time for a new law that
came in to effect in September, however, there are claims that the
new formulations are a flop.
Major drug companies across the US are in process of reformulating
their over-the-counter cold medications in time for a new law that
comes in to effect later this year restricting the sale of drugs
that contain pseudoephedrine.
India's Malladi Drugs and Pharmaceuticals has acquired a US company
to boost its presence in the market for pseudoephedrine, an
ingredient used in cough and cold preparations, reports Phil
Taylor.
The chemicals subsidiary of Germany's Boehringer Ingelheim is
expanding its manufacturing capacity for the nasal decongestant
phenylephrine hydrochloride to tap into what it said is growing
demand worldwide.
